Table 2:
Primary and secondary analyses of the comparative risk of primary and secondary outcomes for new users of trazodone versus atypical antipsychotics within 90 days
| Outcome | Crude HR (95% CI) | Weighted | |||
|---|---|---|---|---|---|
| Cause-specific HR (95% CI) | Events/100 person-years | Risk difference, % (95% CI) | |||
| Trazodone | Atypical antipsychotic | ||||
| Primary intention-to-treat analyses | |||||
| Fall or major osteoporotic fracture | 0.71 (0.60 to 0.85) | 0.89 (0.73 to 1.07) | 23 | 25 | −0.5 (−1.5 to 0.5) |
| All-cause mortality | 0.78 (0.70 to 0.86) | 0.75 (0.66 to 0.85) | 60 | 77 | −4.3 (−6.0 to −2.6) |
| Fall | 0.72 (0.60 to 0.86) | 0.91 (0.75 to 1.11) | 22 | 24 | −0.3 (−1.4 to 0.7) |
| Major osteoporotic fracture | 0.81 (0.59 to 1.12) | 1.03 (0.73 to 1.47) | 8 | 7 | 0.1 (−0.5 to 0.7) |
| Hip fracture | 0.72 (0.48 to 1.08) | 0.92 (0.59 to 1.43) | 5 | 5 | −0.06 (−0.5 to 0.4) |
| Cataract surgery | 0.86 (0.44 to 1.67) | 0.67 (0.33 to 1.34) | 2 | 3 | −0.1 (−0.4 to 0.1) |
| Secondary analyses (censoring on switching exposure group) | |||||
| Fall or major osteoporotic fracture | 0.67 (0.56 to 0.81) | 0.84 (0.69 to 1.02) | 21 | 24 | −0.8 (−1.8 to 0.2) |
| All-cause mortality | 0.78 (0.71 to 0.85) | 0.80 (0.73 to 0.89) | 87 | 105 | −4.4 (−6.3 to −2.5) |
| Fall | 0.68 (0.57 to 0.82) | 0.86 (0.71 to 1.05) | 20 | 23 | −0.6 (−1.6 to 0.4) |
| Major osteoporotic fracture | 0.74 (0.53 to 1.03) | 0.94 (0.65 to 1.34) | 7 | 7 | −0.07 (−0.6 to 0.5) |
| Hip fracture | 0.66 (0.43 to 0.99) | 0.84 (0.53 to 1.32) | 4 | 5 | −0.2 (−0.6 to 0.3) |
Note: CI = confidence interval, HR = hazard ratio.